News and blogs
99 results found.
Repeat COVID-19 jabs offer protection for the immunocompromised
Those with detectable antibodies were less likely to contract the virus or require hospital care if they had COVID-19.
COVID-19 vaccines and blood cancer latest evidence
Lots of information continues to circulate about COVID-19 and vaccinations for immunocompromised people. Here's the latest evidence.
How our research gave vaccine answers to people with blood cancer
Read about how our scientists were able to understand the effectiveness of the COVID-19 vaccine for clinically extremely vulnerable people.
Blood Cancer UK call for UK-wide mask guidance and increased symptomatic testing
As we head into winter, Blood Cancer UK call for guidance to help protect those affected by blood cancer
Three years later: should high risk people still be shielding from Covid?
We take a look at what information and data is available regarding the current impact of Covid on people who are high risk, so that those with blood cancer can make informed decisions about how to live their lives socially.
Blood Cancer UK writes to Health Security Agency
Blood Cancer UK have written to the UK Health Security Agency representing immunocompromised people.
Evusheld will not be rolled out on the NHS
The decision has left many disappointed.
Paxlovid rebound - what we know
Paxlovid rebound is when people recover from covid-19 after taking a course of Paxlovid tablets, but then the infection seems to come back. Find out what this means for people offered treatment with Paxlovid.
Evusheld available in the UK to buy privately
Evusheld is available privately in the UK. Here’s what we know about how to access it.
New campaign launches for the forgotten 500,000 families
Immunocompromised families urge UK government to take action.
What's the latest on Evusheld?
A look at the latest news on Evusheld
Leading charities and clinicians urge Government to secure Evusheld
Over 120 leading clinicians have signed a clinical consensus statement, declaring that the Covid-19 protective antibody treatment Evusheld should be used as soon as possible to protect people most vulnerable to Covid-19.
Making blood cancer and Covid-19 choices that work for you
We know it's still an uncertain time for the blood cancer community, with many people trying to find the right balance between protecting themselves from the virus and looking after their mental well-being.
Survey highlights forgotten pandemic victims
As the country as a whole returns to normal, a quarter of people with blood cancer remain anxious about leaving their home
Evusheld – is it effective?
In this blog, we talk about what the latest research is telling us about how effective Evusheld is.
Our position on Evusheld
Since Evusheld was approved for use by MHRA, we’ve heard from the blood cancer community that one of their greatest concerns is the delay in its rollout across the UK. We wanted to address this directly and explain the work we’ve been doing.
What happens if I have blood cancer and test positive for covid?
We talked to six people with blood cancer about their experience of accessing new antiviral and antibody treatments after they tested positive for covid.
COVID-19 booster jabs and blood cancer
New data reveals just 45% of immunocompromised people in England have had a booster dose of the Covid vaccine.
Find out more about the Covid antibody treatment Evusheld
The treatment consists of two long-acting antibodies called tixagevumab and cilgavimab.
Our response to Evusheld – a treatment to prevent Covid for the immunosuppressed
While we welcome the news of a new Covid treatment for immunosuppressed people – called Evusheld – we call for the Government to urgently set out its approach on how it will use preventative treatments for them.